Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.
Closing out their discussion on the treatment paradigm of relapsed/refractory multiple myeloma, key opinion leaders highlight key takeaways and future directions in care.
During Colorectal Cancer Awareness month, CancerNetwork® sat down with Dorothy Dulko, PhD, to discuss social determinants of cancer.
In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.
Hun Ju Lee, MD, reviews results from part C of the phase 2 SGN35-27 trial for patients with early-stage classical Hodgkin lymphoma treated with brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine.
“MK,” a man aged 67 years, presented with fatigue and nausea to his primary care physician. CT staging scans confirmed the primary tumor and a suspicious left 1.2-cm inguinal lymph node but no distant metastases. MRI of the pelvis revealed complete replacement of the penis with tumor as well as invasion into the scrotum and bilateral groin soft tissue; additionally, early pubic bone invasion was present, with left groin lymphadenopathy. Biopsy verified squamous cell carcinoma of the penis, and discussion with the multidisciplinary team uroradiologist confirmed bony invasion.
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
A rare case of spinal atypical teratoid/rhabdoid tumor is presented in an adult man after presenting with neck pain and bilateral upper extremity paralysis.
Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Lymphedema is a common adverse effect and may negatively impact a patient’s body image.
COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Closing out their review of metastatic urothelial carcinoma management, panelists share what they most look forward to in the evolving treatment landscape.